var data={"title":"Deferiprone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Deferiprone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/44049?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=deferiprone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Deferiprone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301498\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Agranulocytosis/Neutropenia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis. Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and monitor the ANC weekly during therapy. Interrupt deferiprone therapy if neutropenia develops. If infection develops, interrupt deferiprone and monitor the ANC more frequently. Advise patients taking deferiprone to report immediately any symptoms indicative of infection.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13688783\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ferriprox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299487\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Chelating Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301554\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Round dose to the nearest 250 mg (or <sup>1</sup>/<sub>2</sub> tablet) or 2.5 mL (oral solution). If serum ferritin falls consistently below 500 mcg/L, consider temporary treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transfusional iron overload:</b> Oral: Initial: 25 mg/kg 3 times/day (75 mg/kg/day); individualize dose based on response and therapeutic goal; maximum dose: 33 mg/kg 3 times/day (99 mg/kg/day)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301555\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Begin at the low end of dosing range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301558\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301557\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied in patients with severe impairment).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301556\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ANC &lt;1,500/mm<sup>3</sup> and &gt;500/mm<sup>3</sup>: Interrupt treatment immediately and monitor until recovery; do not rechallenge unless the potential benefit outweighs the risk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ANC &lt;500/mm<sup>3</sup>: In addition to treatment interruption, consider hospitalization (and other clinically-appropriate management); do not resume unless the potential benefits outweigh potential risks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Interrupt treatment; monitor ANC more frequently</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307628\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ferriprox: 100 mg/mL (500 mL) [contains fd&amp;c yellow #6 (sunset yellow); cherry-peppermint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ferriprox: 500 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452823\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14280404\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021825s003lbl.pdf&amp;token=7cJE2nn24vBTtutu69e0kgLVTf/4orfAqxPCrLoaEM1WtyfT0b0lZXhHCbXmyrYVNTLXJl76pPH7T/++5we40daoOuwPVqDT2uFMgn8saEI=&amp;TOPIC_ID=17092\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021825s003lbl.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301559\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer in the morning, at midday and in the evening. Administration with food may decrease nausea. Administer after at least a 4-hour interval with medications or supplements containing polyvalent cations (iron, aluminum, zinc).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130979\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299489\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transfusional iron overload:</b> Treatment of transfusional iron overload due to thalassemia syndromes with inadequate response to other chelation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitation of use: Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299486\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Deferiprone may be confused with deferoxamine, deferasirox</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301518\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urine discoloration (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (10%), abdominal distress (&le;10%), abdominal pain (&le;10%), increased appetite (4%), diarrhea (3%), dyspepsia (2%), weight gain (2%), decreased appetite (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (6% to 7%), agranulocytosis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (8%), increased serum AST (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular and skeletal: Arthralgia (10%), back pain (2%), limb pain (2%), arthropathy (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, acute respiratory distress, anaphylactic shock, atrial fibrillation, bruxism, cardiac failure, cerebellar syndrome, cerebral hemorrhage, chills, connective tissue disease (chondropathy), cryptococcosis (cutaneous infection), decreased serum zinc, dehydration, depression, diaphoresis, diplopia, drowsiness, encephalitis (enteroviral), enterocolitis, epistaxis, fever, furuncle, gastric ulcer, glycosuria, hemoglobinuria, hemoptysis, hepatitis A, hepatomegaly, hypersensitivity reaction, hypertension, hypospadias, hypotension, IgA vasculitis, increased creatine phosphokinase, increased intracranial pressure, increased serum bilirubin, jaundice, metabolic acidosis, motor dysfunction (pyramidal tract syndrome), multi-organ failure, myositis, obsessive compulsive disorder, pancreatitis, pancytopenia, papilledema, parotid gland enlargement, periorbital edema, peripheral edema, pharyngitis, pneumonia, pruritus, psychomotor disturbance, pulmonary embolism, pustular rash, rectal hemorrhage, retinal toxicity, seizure, sepsis, skin photosensitivity, skin rash, subcutaneous abscess, thrombocythemia, torsades de pointes, trismus, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301503\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to deferiprone or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301504\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Agranulocytosis//Neutropenia: <b>[US Boxed Warning]: May cause agranulocytosis, which could lead to serious infections (some fatal). Agranulocytosis may be preceded by neutropenia; monitor absolute neutrophil count (ANC) prior to treatment initiation and weekly during therapy. If infection develops, interrupt treatment and monitor ANC more frequently. Patients should promptly report any symptoms which may indicate infection. Interrupt treatment if neutropenia (ANC &lt;1,500/mm<sup>3</sup>) develops;</b> withhold any other medications which may also be associated with neutropenia; monitor CBC, corrected WBC, ANC, and platelets daily until ANC recovery. If ANC &lt;500/mm<sup>3</sup>, consider hospitalization (and other clinically appropriate management); do not resume or rechallenge unless the potential benefits outweigh potential risks. Neutropenia and agranulocytosis were generally reversible upon discontinuation. The mechanism for deferiprone-induced agranulocytosis is not known. Avoid concurrent use with other agents associated with neutropenia (or agranulocytosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Elevations in ALT values have been observed; monitor ALT and consider treatment interruption for persistent elevations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions have been reported (eg, Henoch-Sch&ouml;nlein purpura [immunoglobulin A vasculitis], urticaria, and periorbital edema with skin rash).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Zinc deficiency: Lower plasma zinc concentrations have been observed; monitor zinc levels and supplement if necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301538\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of UGT1A6, UGT1A9, UGT2B15, UGT2B7</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13320101\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=17092&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<b> Exceptions: </b>Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Myelosuppressive Agents: May enhance the neutropenic effect of Deferiprone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">UGT1A6 Inhibitors: May increase the serum concentration of Deferiprone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301499\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301500\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in animal reproduction studies. Although there is limited data in humans, deferiprone may cause fetal harm if administered during pregnancy. During treatment with deferiprone in women of reproductive potential, pregnancy should be avoided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301502\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if deferiprone is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307625\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken with food to decrease nausea. Allow at least a 4-hour interval with foods containing iron, aluminum, and zinc.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307626\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum ferritin (every 2-3 months); ANC (at baseline and weekly during treatment); if ANC &lt;1,500/mm<sup>3</sup>, monitor CBC, WBC (corrected for nucleated RBCs), ANC, and platelets daily until ANC recovery; ALT (monthly); zinc levels; signs or symptoms of infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301542\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Iron-chelating agent with affinity for ferric ion (iron III); binds to ferric ion and forms a 3:1 (deferiprone:iron) complex which is excreted in the urine. Has a lower affinity for other metals such as copper, aluminum, and zinc.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13301545\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 1.6 L/kg (in thalassemia patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &lt;10%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily by UGT 1A6; major metabolite (3-O-glucuronide) lacks iron-binding capacity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Tablets and oral solution are considered to be bioequivalent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half life elimination: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: ~1-2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (75% to 90%; primarily as metabolite)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322919\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ferriprox Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (500 mL): $7,011.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ferriprox Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $7,011.65</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13733212\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Feripon (BD);</li>\n      <li>Ferriprox (AE, AR, AT, AU, BB, BE, BH, BR, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IT, JO, KR, KW, LK, LT, LU, LV, MT, NL, NO, NZ, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, TH, TR, VN);</li>\n      <li>Kelfer (AE, GR, IN, MY, SG, TH, TW, VN);</li>\n      <li>Neferi (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ceci A, Baiardi P, Felisi M, et al, &ldquo;The Safety and Effectiveness of Deferiprone in a Large-Scale, 3-Year Study in Italian patients,&rdquo; <i>Br J Haematol</i>, 2002, 118(1):330-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferiprone-drug-information/abstract-text/12100170/pubmed\" target=\"_blank\" id=\"12100170\">12100170</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen AR, Galanello R, Piga A, et al, Safety and Effectiveness of Long-Term Therapy With the Oral Iron Chelator Deferiprone,&rdquo; <i>Blood</i>, 2003, 102(5):1583-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferiprone-drug-information/abstract-text/12763939/pubmed\" target=\"_blank\" id=\"12763939\">12763939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferriprox (deferiprone) tablets [prescribing information]. Rockville, MD: ApoPharma USA Inc; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferriprox (deferiprone) solution [prescribing information]. Rockville, MD: ApoPharma USA Inc; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neufeld EJ, &ldquo;Oral Chelators Deferasirox and Deferiprone for Transfusional Iron Overload in Thalassemia Major: New Data, New Questions,&rdquo; <i>Blood</i>, 2006, 107(9):3436-41.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 17092 Version 81.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F13301498\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13688783\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13299487\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13301554\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F13301555\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13301558\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13301557\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F13301556\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13307628\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20452823\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F14280404\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13301559\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130979\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13299489\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13299486\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13301518\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13301503\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13301504\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13301538\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13320101\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13301499\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13301500\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13301502\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F13307625\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13307626\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13301542\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F13301545\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322919\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F13733212\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/17092|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=deferiprone-patient-drug-information\" class=\"drug drug_patient\">Deferiprone: Patient drug information</a></li></ul></div></div>","javascript":null}